| candesartan versus placebo | |||
| CHARM preserved, 2003 | candesartan target dose 32 mg once daily versus placebo | patients with NYHA II-IV heart failure and LVEF higher than 40% | double blind Follow-up duration: 36.6 months 26 countries |
| ibesartan versus placebo | |||
| I-PRESERVE (McMurray), 2008 NCT00095238 | ibersatan 300mg daily versus placebo | patients with NYHA II, III, or IV heart failure and an ejection fraction of at least 45% | double blind Follow-up duration: 49.5 months Western Europe, Eastern Europe, North America, South America, South Africa, and Australia |
| LCZ696 versus valsartan | |||
| PARAMOUNT, 2012 NCT00887588 | LCZ696 titrated to 200 mg twice daily for 36 weeks versus valsartan titrated to 160 mg twice daily, | double-blind Follow-up duration: 12 weeks | |
| perindopril versus placebo | |||
| PEP CHF, 2006 | perindopril, 4 mg/day versus placebo | patients aged >=70 years with a diagnosis of heart failure, treated with diuretics and an echocardiogram suggesting diastolic dysfunction and excluding substantial LV systolic dysfunction or valve disease | double blind Follow-up duration: 26.2 months (range 12-54.2m) Europe |
| spironolactone versus placebo | |||
| TOPCAT, 2014 NCT00094302 | spironolactone (15 to 45 mg daily) versus placebo | patients with heart failure and a preserved left ventricular ejection fraction of 45% or more | double-blind Follow-up duration: 3.3 years |
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
